Page last updated: 2024-08-05 11:46:51
caprolactams
A lactam in which the amide bond is contained within a seven-membered ring, which includes the amide nitrogen and the carbonyl carbon.
ChEBI ID: 23000
Members (7)
| Member | Definition | Role |
|---|---|---|
| (5R)-5-tert-butyl-1-[(3S)-3-[(4-methylphenyl)thio]-3-phenylpropyl]-2-azepanone | (5R)-5-tert-butyl-1-[(3S)-3-[(4-methylphenyl)thio]-3-phenylpropyl]-2-azepanone | |
| (5R)-5-tert-butyl-1-[(3S)-3-phenyl-3-(phenylthio)propyl]-2-azepanone | (5R)-5-tert-butyl-1-[(3S)-3-phenyl-3-(phenylthio)propyl]-2-azepanone | |
| alsterpaullone | An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole. | alsterpaullone |
| ANA-12 | A secondary carboxamide that is anthranilic acid in which the carboxy group has undergone condensation with the primary amino group of alpha-amino-epsilon-caprolactam, while the aryl-amino group has undergone condensation with the carboxy group of 1-benzothiophene-2-carboxylic acid. It is a selective, non-competitive antagonist of tropomyosin receptor kinase B (TrkB, also known as tyrosine receptor kinase B). | ANA-12 |
| caprolactam | A member of the class of caprolactams that is azepane substituted by an oxo group at position 2. | epsilon-caprolactam |
| ciliatamide a | A lipopeptide that contains N-methylphenylalanine and lysine as the amino acid residues linked to a dec-9-enoyl moiety via an amide linkage (the R,R stereoisomer). It is isolated from the deep sea sponge Aaptos ciliata and exhibits antileishmanial activity. | ciliatamide A |
| rucaparib | A member of the class of azepinoindoles that is 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one carrying additional 4-[(methylamino)methyl]phenyl and fluoro substituents at positions 2 and 8 respectively. It is an inhibitor of poly (ADP-ribose) polymerase and is used (as the camsylate salt) as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation. | rucaparib |
Research
Studies (1,005)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 216 (21.49) | 18.7374 |
| 1990's | 48 (4.78) | 18.2507 |
| 2000's | 169 (16.82) | 29.6817 |
| 2010's | 400 (39.80) | 24.3611 |
| 2020's | 172 (17.11) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 42 (3.80%) | 5.53% |
| Reviews | 64 (5.80%) | 6.00% |
| Case Studies | 28 (2.54%) | 4.05% |
| Observational | 3 (0.27%) | 0.25% |
| Other | 967 (87.59%) | 84.16% |